

BioMaxima cleared to sell tests for the monkey pox virus diagnostics

BioMaxima SA, a leading Polish manufacturer of laboratory diagnostics systems, announced today that the company has been cleared to sell its genetic test for monkey pox. The firm recently announced record Q1 profit.

The **MPXV Real Time PCR LAB-KIT** test is intended for the qualitative identification of the genetic material of the monkey pox virus (MPXV). Test material may come from sputum, nasopharyngeal swab, tonsil, throat, skin lesions, blisters, body fluids, pustules and skin wounds. Virus DNA is extracted from clinical samples, amplified using real-time amplification and detected using specific primers and a fluorescent reporter dye probe.

The laboratory validation confirms that **MPXV Real Time PCR LAB-KIT** is a **high-quality genetic test with high sensitivity, detecting as few as 2 copies of pathogen genes in 20 µL of the PCR reaction mixture**. The test is provided ready in test tubes, and it is compatible with the majority of qPCR thermocyclers.

– BioMaxima specializes in infectious disease diagnostic technologies and we constantly monitor emerging epidemic threats, including the monkey pox virus. Similar to other genetic tests from the LAB-KIT line, the MPXV Real Time PCR LAB-KIT test is prepared in lyophilized form. This enables extended shelf life and safe transport and storage at room temperature of the tests, which will be important in the upcoming summer season – says Łukasz M. Urban, CEO of BioMaxima SA

BioMaxima also registered **Monkeypox Ag Rapid Test**, which is a rapid immunochromatographic test for qualitative detection of the presence of the monkey pox virus antigen. The test material may be whole blood, plasma, serum or swab from rash blisters. No special equipment is required to perform the rapid test.

The tests have been registered with the Polish Office for Registration of Medical Products (URPL).

According to the World Health Organization (WHO) data published on June 8, already 1285 cases have been reported in 28 countries (outside of African endemic areas). Monkey pox infection cases were detected in Germany, Switzerland, Spain, Belgium, Italy, Portugal, Great Britain, Hungary, Austria and Sweden and recently also in Poland.

The BioMaxima Capital Group generated a record 93,596 thousand PLN net revenues in the first quarter of 2022, which is an increase year-on-year of 351%. EBITDA amounted to PLN 30,703 thousand, and the group's net profit for Q1 2022 was PLN 24,194 thousand PLN and was 386 percent higher than in Q1 2021.

BioMaxima S.A., a company listed on the Warsaw Stock Exchange, is a Polish manufacturer of infectious disease diagnostics systems, including microbiology, and antibiotic susceptibility testing (AST), as well as a wide range of in vitro diagnostic reagents and equipment. BioMaxima supplies its products to over 2 thousand laboratories in Poland and exports to more than 60 international markets.

Press contact:

Rafał Buława

rbulawa@komunikacjaplus.pl

www.biomaxima.com

tel. +48 601 966 922